Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib — Stella

Home/Non-Small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Non-Small Cell Lung Cancer trials

Trial locations(1 site)

China

Peking University Shenzhen Hospital, Shenzhen, Guangdong

Key details

Sponsor

Peking University Shenzhen Hospital

Collaborators

Shenzhen People's Hospital, Longgang District People's Hospital of Shenzhen

Enrollment target

~20 participants

Started

January 2026

Primary completion

December 2028

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.